Ebos GroupASX:EBO +3.13%77 Return-on-Tangible-Equity is Negative Tangible Equity% as of Dec. 2025. GuruFocus rates ASX:EBO with a GF Score™ of 77/100 and a GF Value™ of A$33.68 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 111 Medical Distribution companies, Ebos Group ranks better than 99.1% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ebos Group's annualized net income for the quarter that ended in Dec. 2025 was A$252 Mil. Ebos Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$-107 Mil. Therefore, Ebos Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was Negative Tangible Equity%.
The historical rank and industry rank for Ebos Group's Return-on-Tangible-Equity or its related term are showing as below:
ASX:EBO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 86.67 Med: 189.88 Max: 557.92
Current: Negative Tangible Equity
During the past 13 years, Ebos Group's highest Return-on-Tangible-Equity was 557.92%. The lowest was 86.67%. And the median was 189.88%.
ASX:EBO's Return-on-Tangible-Equity is ranked better than 99.1% of 111
companies
in the Medical Distribution industry
Industry Median: 8.81
vs ASX:EBO: Negative Tangible Equity
Ebos Group (ASX:EBO) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Ebos Group Return-on-Tangible-Equity Related Terms
Ebos Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Ebos Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EBO vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Ebos Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Ebos Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
Ebos Group (ASX:EBO) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ebos Group and its competitors. Over the past decade, Ebos Group's Return-on-Tangible-Equity has ranged from 86.67 to 557.92. According to the industry distribution chart, Ebos Group ranks #1 out of 111 companies in the Medical Distribution industry, placing it in the top 0.90000000000001%.
Is Ebos Group's Return-on-Tangible-Equity too high?
Ebos Group's current Return-on-Tangible-Equity is Negative Tangible Equity%. Over the past 10 years, this metric has ranged from a low of 86.67 to a high of 557.92. Based on the distribution chart, Ebos Group ranks #1 out of 111 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Ebos Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #1 out of 111 companies for Return-on-Tangible-Equity. This places Ebos Group in the top 1% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 8.81. Historically, Ebos Group's own Return-on-Tangible-Equity has ranged from 86.67 to 557.92 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.81, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$33.68, compared to a current price of A$17.47 — trading 48.1% below its estimated fair value. The current Return-on-Tangible-Equity is Negative Tangible Equity%. Ebos Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$17.47 is trading 48.1% below its estimated GF Value™ of A$33.68.
GuruFocus considers Ebos Group to be Significantly Undervalued.
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score
Get the complete analysis for ASX:EBO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
